

Atty's Docket No.: P29138

Application No.: 10/564,407

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Akiko ITAI et al.

Group Art Unit : 4173


Appln. No. : 10/564,407
(National Stage of PCT/JP2004/010558)

Examiner : Paul W. DICKINSON

I.A. Filed : July 16, 2004

Confirmation No.: 3483

For : MEDICAMENT FOR TREATMENT OF DERMAL PIGMENTATION



SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop AMENDMENT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98 and supplemental to the Information Disclosure Statements filed July 3, 2006 and February 6, 2008, Applicants hereby bring to the attention of the Examiner the following documents cited in a Russian Office Action for Russian Application No. 2006104697, of which the above Application is a family member:

- (1) CA 2431083, June 27, 2006; Applicants note that this document is a family member of U.S. Patent Application Publication No. 2004/259877 A1 (MUTO et al.), December 23, 2004, which was already brought to the Examiner's attention in the Information Disclosure Statement of July 3, 2006;
- (2) WO 97/35618 A1, October 2, 1997;
- (3) "Chemical Encyclopaedia," Moscow, "The Soviet Encyclopaedia." 1983, pp. 130-131.

Copies of the above-listed documents, the Russian Office Action and an English translation thereof are enclosed together with a completed copy of the PTO-1449 Form listing these documents.


Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

In accordance with 37 C.F.R. 1.97(e), the undersigned hereby states that each item of information contained in the Information Disclosure Statement were first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement. Of course, this statement does not apply to information that has previously been cited by Applicant or the Examiner in the present application as that information is already of record and no certification is necessary.

Moreover, Applicants note that although a family member of document (1) was already brought to the Examiner's attention in a previous Information Disclosure Statement, the particular Canadian document was first cited in the Russian Office Action. Therefore, Applicants believe that the above statement under 37 C.F.R. § 1.97(e) encompasses document (1). However, if a fee is deemed necessary for the consideration of document (1) or any other submitted information, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Akiko ITAI et al,


Bruce H. Bernstein
Reg. No. 29,027 42,920

July 14, 2008
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191